BR0009484A - Imunoensaio em série para câncer - Google Patents
Imunoensaio em série para câncerInfo
- Publication number
- BR0009484A BR0009484A BR0009484-6A BR0009484A BR0009484A BR 0009484 A BR0009484 A BR 0009484A BR 0009484 A BR0009484 A BR 0009484A BR 0009484 A BR0009484 A BR 0009484A
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- serial
- breast cancer
- ndp
- kinase
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
Abstract
"IMUNOENSAIO EM SéRIE PARA CâNCER". A identificação e caracterização de fatores de risco e suas implicações moleculares na fisiopatologia de doenças humanas tal como câncer é essencial para projetar exames de diagnóstico eficientes e compostos terapêuticos. Esteróides estrogênicos, sob condições fisiológicas normais, demonstraram desempenhar uma função crítica em diversos tecidos. A resposta de tal variedade de tecidos à estimulação por estrogênio pode explicar em parte seu papel ativo no desenvolvimento e progressão de doenças humanas diferentes, particularmente câncer de mama. Na busca de fatores celulares que respondem ao estrogênio em células matriz de carcinomas de mama humanos primários obtidos de biópsias de tumor, dois marcadores celulares, uma isoenzima de leucina aminopeptidase putativa (LAPase; EC 3.4.11.1) de celulas matriz de carcinomas de mama humanos primários obtidos de biópsias de tumor, e NDP-Quinase/Nm23 (EC 2.7.4.6) citosólica de células HL60 foram identificados. Anticorpos monoclonais contra cada marcador celular foram produzidos. Determinação da presença destes dois marcadores, quer sozinho ou em combinação pode ser utilizada para detectar câncer de mama, e em particular, metástase associada. Assim, esta invenção refere-se ao uso de ambos os anticorpos monoclonais LAP e NDP-Quinase/Nm23 em conjunto num imunoensaio baseado em matriz sólida em série para teste de primeira linha confirmatório baseado em sangue para câncer de mama.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002267481A CA2267481A1 (en) | 1999-03-30 | 1999-03-30 | Critical interdependency: from the role of estrogen on breast cancer to the susceptibility of women towards hiv infection |
PCT/CA2000/000330 WO2000060357A1 (en) | 1999-03-30 | 2000-03-30 | Tandem immuno-assay for cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0009484A true BR0009484A (pt) | 2002-02-05 |
Family
ID=4163415
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0009484-6A BR0009484A (pt) | 1999-03-30 | 2000-03-30 | Imunoensaio em série para câncer |
BR0009483-8A BR0009483A (pt) | 1999-03-30 | 2000-03-30 | Anticorpo monoclonal contra leucina aminopeptidase estimulada por estrogênio |
BR0009485-4A BR0009485A (pt) | 1999-03-30 | 2000-03-30 | Método e composições para evitar ou reduzir infecção por hiv pelo uso de inibidores para leucina aminopeptidase |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0009483-8A BR0009483A (pt) | 1999-03-30 | 2000-03-30 | Anticorpo monoclonal contra leucina aminopeptidase estimulada por estrogênio |
BR0009485-4A BR0009485A (pt) | 1999-03-30 | 2000-03-30 | Método e composições para evitar ou reduzir infecção por hiv pelo uso de inibidores para leucina aminopeptidase |
Country Status (8)
Country | Link |
---|---|
US (4) | US6649743B1 (pt) |
EP (3) | EP1114322A1 (pt) |
CN (3) | CN1362970A (pt) |
AU (3) | AU3413100A (pt) |
BR (3) | BR0009484A (pt) |
CA (1) | CA2267481A1 (pt) |
MX (3) | MXPA01010984A (pt) |
WO (3) | WO2000059944A1 (pt) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10054899C2 (de) | 2000-12-08 | 2003-08-21 | Tubag Trass Zement Stein | Vorrichtung und Verfahren zum Aufbringen von Dünnbettmörtel |
AU2002230049A1 (en) * | 2001-01-30 | 2002-08-12 | The Provost, Fellows And Scholars Of The College Of The Holy And Unidivided Trinity Of Queen Elizabe | Thioredoxin derived from h. pylori, which is capable of inhibiting nf-kappa b activation |
EP2341350B1 (en) * | 2003-09-20 | 2017-11-08 | Electrophoretics Limited | Diagnostic method for brain damage-related disorders based on detection of dj-1 |
GB0404419D0 (en) | 2004-02-27 | 2004-03-31 | Intelligent Textiles Ltd | Electrical components and circuits constructed as textiles |
US7197427B2 (en) * | 2004-03-31 | 2007-03-27 | Genworth Financial Inc. | Method for risk based testing |
WO2008101133A2 (en) * | 2007-02-14 | 2008-08-21 | Cedars-Sinai Medical Center | Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease |
ATE477497T1 (de) * | 2004-12-08 | 2010-08-15 | Cedars Sinai Medical Center | Verfahren zur diagnose von morbus crohn |
WO2008109782A2 (en) * | 2007-03-06 | 2008-09-12 | Cedars-Sinai Medical Center | Diagnosis of inflammatory bowel disease in children |
CN100376680C (zh) * | 2005-11-01 | 2008-03-26 | 暨南大学 | 双重靶效应基因嵌合重组体及其构建方法和应用 |
DE102006023535B4 (de) * | 2006-05-19 | 2008-12-18 | Keiper Gmbh & Co.Kg | Getriebestufe für einen Stellantrieb |
US20100190162A1 (en) * | 2007-02-26 | 2010-07-29 | Cedars-Sinai Medical Center | Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease |
WO2008137762A2 (en) * | 2007-05-04 | 2008-11-13 | Cedars-Sinai Medical Center | Methods of diagnosis and treatment of crohn's disease |
WO2008116150A2 (en) | 2007-03-21 | 2008-09-25 | Cedars-Sinai Medical Center | Ileal pouch-anal anastomosis (ipaa) factors in the treatment of inflammatory bowel disease |
US20100184050A1 (en) * | 2007-04-26 | 2010-07-22 | Cedars-Sinai Medical Center | Diagnosis and treatment of inflammatory bowel disease in the puerto rican population |
US20080318063A1 (en) * | 2007-06-22 | 2008-12-25 | Anderson Jerrel C | Glass laminates with improved weatherability |
WO2009143309A2 (en) * | 2008-05-21 | 2009-11-26 | Trustees Of Dartmouth College | Female reproductive tract and anal prophylaxes |
US20110177969A1 (en) * | 2008-10-01 | 2011-07-21 | Cedars-Sinai Medical Center | The role of il17rd and the il23-1l17 pathway in crohn's disease |
US20110189685A1 (en) * | 2008-10-22 | 2011-08-04 | Cedars-Sinai Medical Center | Methods of using jak3 genetic variants to diagnose and predict crohn's disease |
US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
WO2010075579A2 (en) | 2008-12-24 | 2010-07-01 | Cedars-Sinai Medical Center | Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy |
EP2550362B1 (en) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
PT2691530T (pt) | 2011-06-10 | 2018-05-10 | Univ Oregon Health & Science | Glicoproteínas e vectores recombinantes cmv |
US20130189754A1 (en) | 2011-09-12 | 2013-07-25 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
CN112870368A (zh) | 2013-03-27 | 2021-06-01 | 西达-赛奈医疗中心 | 通过抑制tl1a的功能和相关信号传导途径来减轻并逆转纤维化和炎症 |
EP3022295A4 (en) | 2013-07-19 | 2017-03-01 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
WO2015133935A1 (ru) * | 2014-03-04 | 2015-09-11 | Григорий Дмитриевич КАМИНСКИЙ | Способ и устройство прогнозирования времени развития вич-инфекции у женщин после родов |
EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
KR20180103823A (ko) | 2015-12-18 | 2018-09-19 | 인텔리전트 텍스타일 리미티드 | 전도성 직물, 전도성 직물 직조방법 및 이에 관한 장치 |
EP3430172A4 (en) | 2016-03-17 | 2019-08-21 | Cedars-Sinai Medical Center | METHOD FOR DIAGNOSIS OF INFLAMMATORY ENDURANCE THROUGH RNASET2 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5678600A (en) * | 1979-12-03 | 1981-06-27 | Eiken Kagaku Kk | Method for measuring activity of leucine aminopeptidase in serum |
US5179008A (en) | 1989-02-09 | 1993-01-12 | Wisconsin Alumni Research Foundation | Hybridoma and monoclonal antibody to FHAP |
US5001052A (en) | 1989-02-09 | 1991-03-19 | Wisconsin Alumni Research Foundation | Immunoassay for FHAP and antibody useful therewith |
CA2108533C (en) | 1992-10-16 | 2002-10-08 | Gabriel Pulido-Cejudo | Monoclonal antibodies directed against ndp-kinase |
EP0900381A1 (en) * | 1996-04-26 | 1999-03-10 | Children's Medical Center Corporation | Non-invasive enzyme screen for tissue remodelling-associated conditions |
-
1999
- 1999-03-30 CA CA002267481A patent/CA2267481A1/en not_active Abandoned
-
2000
- 2000-03-30 AU AU34131/00A patent/AU3413100A/en not_active Abandoned
- 2000-03-30 BR BR0009484-6A patent/BR0009484A/pt not_active IP Right Cessation
- 2000-03-30 BR BR0009483-8A patent/BR0009483A/pt not_active IP Right Cessation
- 2000-03-30 MX MXPA01010984A patent/MXPA01010984A/es unknown
- 2000-03-30 CN CN00807918A patent/CN1362970A/zh active Pending
- 2000-03-30 WO PCT/CA2000/000332 patent/WO2000059944A1/en not_active Application Discontinuation
- 2000-03-30 EP EP00913983A patent/EP1114322A1/en not_active Withdrawn
- 2000-03-30 WO PCT/CA2000/000330 patent/WO2000060357A1/en not_active Application Discontinuation
- 2000-03-30 AU AU34132/00A patent/AU3413200A/en not_active Abandoned
- 2000-03-30 CN CN00807919A patent/CN1382059A/zh active Pending
- 2000-03-30 EP EP00912307A patent/EP1114064A1/en not_active Withdrawn
- 2000-03-30 MX MXPA01010995A patent/MXPA01010995A/es unknown
- 2000-03-30 CN CN00807917A patent/CN1351714A/zh active Pending
- 2000-03-30 US US09/538,831 patent/US6649743B1/en not_active Expired - Fee Related
- 2000-03-30 WO PCT/CA2000/000331 patent/WO2000059534A1/en not_active Application Discontinuation
- 2000-03-30 MX MXPA01010985A patent/MXPA01010985A/es unknown
- 2000-03-30 US US09/538,827 patent/US6406701B1/en not_active Expired - Fee Related
- 2000-03-30 AU AU35464/00A patent/AU3546400A/en not_active Abandoned
- 2000-03-30 EP EP00912306A patent/EP1113812A1/en not_active Withdrawn
- 2000-03-30 BR BR0009485-4A patent/BR0009485A/pt not_active Application Discontinuation
- 2000-03-30 US US09/538,200 patent/US6521415B1/en not_active Expired - Fee Related
-
2003
- 2003-11-12 US US10/705,991 patent/US20040106143A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN1362970A (zh) | 2002-08-07 |
CN1351714A (zh) | 2002-05-29 |
EP1113812A1 (en) | 2001-07-11 |
BR0009483A (pt) | 2002-02-05 |
WO2000059534A1 (en) | 2000-10-12 |
EP1114064A1 (en) | 2001-07-11 |
AU3546400A (en) | 2000-10-23 |
CA2267481A1 (en) | 2000-09-30 |
WO2000059944A1 (en) | 2000-10-12 |
MXPA01010995A (es) | 2002-06-04 |
US6406701B1 (en) | 2002-06-18 |
WO2000060357A1 (en) | 2000-10-12 |
AU3413200A (en) | 2000-10-23 |
US20040106143A1 (en) | 2004-06-03 |
US6521415B1 (en) | 2003-02-18 |
CN1382059A (zh) | 2002-11-27 |
MXPA01010985A (es) | 2002-06-04 |
EP1114322A1 (en) | 2001-07-11 |
MXPA01010984A (es) | 2002-06-04 |
US6649743B1 (en) | 2003-11-18 |
BR0009485A (pt) | 2002-02-05 |
AU3413100A (en) | 2000-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0009484A (pt) | Imunoensaio em série para câncer | |
Sokoloff et al. | A dual‐monoclonal sandwich assay for prostate‐specific membrane antigen: Levels in tissues, seminal fluid and urine | |
De Potter et al. | The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues | |
AU720802B2 (en) | Detection of cancer by assaying for cancer-specific antigens having linked oligosaccharides which are at least triantennary | |
US20070015227A1 (en) | Non-invasive enzyme screen for tissue remodeling associated conditions | |
JP2006311860A (ja) | 組織のリモデリングに関連した状態のための非観血的酵素スクリーン | |
US20080293162A1 (en) | Methods and compositions for diagnosing neoplastic disease | |
Protheroe et al. | Urinary concentrations of the soluble adhesion molecule E-cadherin and total protein in patients with bladder cancer | |
Chu | Prostate‐specific antigen in screening of prostate cancer | |
Griffiths et al. | The laboratory diagnosis of prostatic adenocarcinoma | |
Vural et al. | The relationship between preoperative CEA and CA19-9 status and patient characteristics and lymph node involvement in early-stage colon cancer. | |
Ban et al. | Immunologic markers and the diagnosis of prostatic cancer | |
CA2303598A1 (en) | Tandem immuno-assay for cancer | |
Chopin et al. | Detection of transitional cell carcinoma in bladder by intravesical injection of monoclonal antibodies | |
US8101371B2 (en) | Methods for the diagnosis of genitourinary cancer | |
AU757490B2 (en) | Detection of cancer by assaying for cancer-specific antigens having linked oligosaccharides which are at least triantennary | |
AU775537B2 (en) | Non-invasive enzyme screen for tissue remodelling-associated conditions | |
CA2303505A1 (en) | A monoclonal antibody against estrogen stimulated leucine aminopeptidase | |
Chu | Prostate specific antigen (PSA): the historical perspective | |
Ferrer et al. | Prognostic relevance of plasminogen activator u-PA in human breast cancer | |
Gupta et al. | A New Immunologic Method for Detection of Occult Breast Cancer. | |
Monti et al. | The utility of flow cytometric analysis on the preoperative management of breast tumor | |
Casati et al. | Utility of strict follow-up after surgery for breast cancer | |
Ferrer et al. | Tissue-type plasminogen activator (t-PA) and steroid hormone receptors in breast cancer | |
Raveh et al. | Mammographic needle localization biopsy of non palpable breast lesions. A review of 197 patients with pathological correlation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADES. |
|
B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1971 DE 14/10/2008 POR TER SIDO INDEVIDO. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A TAXA DE RESTAURACAO DA 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO 1976 DE 18/11/2008. |